NASDAQ NMS - GLOBAL MARKET · DMAC
+0.00% · +$0.0000 · Vol 77.6K
Market closed · last close 4:00 PM ET · price as of 16:01:38 ET
DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc

Biotechnology
$6.52
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
DMAC
DiaMedica Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

41/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DMAC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DMAC catalysts
About DiaMedica Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2007
Employees
35
Country
US

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.58
Day high
$6.73
Day low
$6.50
Previous close
$6.52
52W high
$9.39
-30.56% from high
52W low
$5.30
30% of range
Market cap
$351.6M
EPS
$-0.1900
Beta
1.41
Shares out
53.9M
Volume
77.6K
0.49× rel vol
Avg volume
159.5K
VWAP
$6.55
Price history computed in-house
1W
-2.40%
1M
-3.19%
3M
+10.32%
1Y
+6.71%
YTD
-18.09%
SMA 50 $6.76 · below
SMA 200 $7.19 · below
52W position 30%

DMAC overview

Veridion Score
41
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DMAC.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DMAC Form 4 filings
Public disclosures

Congress activity in DMAC

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DMAC in the cached public ledger.

Federal contracts

DMAC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DMAC in this window.
Lobbying spend

DMAC lobbying filings, year to date.

Registered lobbying filings matched to DiaMedica Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DMAC in this window.
Loading news for DMAC
Analyst ratings
Sovereign unlock shows live analyst consensus for DMAC.
Options
Sovereign unlock shows live options positioning for DMAC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.